These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Springer AD; Dowdy SF Nucleic Acid Ther; 2018 Jun; 28(3):109-118. PubMed ID: 29792572 [TBL] [Abstract][Full Text] [Related]
30. Ligand conjugate SAR and enhanced delivery in NHP. Holland RJ; Lam K; Ye X; Martin AD; Wood MC; Palmer L; Fraser D; McClintock K; Majeski S; Jarosz A; Lee ACH; Thi EP; Judge A; Heyes J Mol Ther; 2021 Oct; 29(10):2910-2919. PubMed ID: 34091052 [TBL] [Abstract][Full Text] [Related]
31. 5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates. Parmar R; Willoughby JL; Liu J; Foster DJ; Brigham B; Theile CS; Charisse K; Akinc A; Guidry E; Pei Y; Strapps W; Cancilla M; Stanton MG; Rajeev KG; Sepp-Lorenzino L; Manoharan M; Meyers R; Maier MA; Jadhav V Chembiochem; 2016 Jun; 17(11):985-9. PubMed ID: 27121751 [TBL] [Abstract][Full Text] [Related]
32. Liver cancer cells as the model for developing liver-targeted RNAi therapeutics. Hou B; Qin L; Huang L Biochem Biophys Res Commun; 2023 Feb; 644():85-94. PubMed ID: 36640667 [TBL] [Abstract][Full Text] [Related]
33. Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease. He X; Chang Z; Chen F; Zhang W; Sun M; Shi T; Liu J; Chen P; Zhang K; Guan S; Zhao Z; Li M; Dong WF; Shao D; Yang C Acta Biomater; 2024 Jan; 174():281-296. PubMed ID: 37951519 [TBL] [Abstract][Full Text] [Related]
34. Prolonged cultured human hepatocytes as an in vitro experimental system for the evaluation of potency and duration of activity of RNA therapeutics: Demonstration of prolonged duration of gene silencing effects of a GalNAc-conjugated human hypoxanthine phosphoribosyl transferase (HPRT1) siRNA. Yang Q; Humphreys SC; Lade JM; Li AP Biochem Pharmacol; 2021 Jul; 189():114374. PubMed ID: 33358826 [TBL] [Abstract][Full Text] [Related]
35. Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease. Rider D; Chivers S; Aretz J; Eisermann M; Löffler K; Hauptmann J; Morrison E; Campion G Toxicol Sci; 2022 Sep; 189(2):237-249. PubMed ID: 35737426 [TBL] [Abstract][Full Text] [Related]
36. Synthesis of 5'-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies. Cedillo I; Chreng D; Engle E; Chen L; McPherson AK; Rodriguez AA Molecules; 2017 Aug; 22(8):. PubMed ID: 28809818 [TBL] [Abstract][Full Text] [Related]
37. Lu J; Swearingen E; Hardy M; Collins P; Wu B; Yuan E; Lu D; Li CM; Wang S; Ollmann M Mol Ther Nucleic Acids; 2022 Jun; 28():423-434. PubMed ID: 35505960 [TBL] [Abstract][Full Text] [Related]
38. Combination treatment of mannose and GalNAc conjugated small interfering RNA protects against lethal Marburg virus infection. Ye X; Holland R; Wood M; Pasetka C; Palmer L; Samaridou E; McClintock K; Borisevich V; Geisbert TW; Cross RW; Heyes J Mol Ther; 2023 Jan; 31(1):269-281. PubMed ID: 36114672 [TBL] [Abstract][Full Text] [Related]
39. Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs. Schlegel MK; Matsuda S; Brown CR; Harp JM; Barry JD; Berman D; Castoreno A; Schofield S; Szeto J; Manoharan M; Charissé K; Egli M; Maier MA Nucleic Acids Res; 2021 Nov; 49(19):10851-10867. PubMed ID: 34648028 [TBL] [Abstract][Full Text] [Related]
40. The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies. Janas MM; Harbison CE; Perry VK; Carito B; Sutherland JE; Vaishnaw AK; Keirstead ND; Warner G Toxicol Pathol; 2018 Oct; 46(7):735-745. PubMed ID: 30139307 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]